New Triple-Threat attack on blood cancer tested in patients
Disease control
Ongoing
This study is testing whether a combination of three drugs—acalabrutinib, umbralisib, and ublituximab—can control the growth of chronic lymphocytic leukemia (CLL). It is enrolling adults with CLL, including those whose cancer has come back after treatment and those who have never…
Phase: PHASE2 • Sponsor: Jennifer R. Brown, MD, PhD • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC